Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 693

1.

Assessing the anticoagulant effect of dabigatran in children: An in vitro study.

Dietrich K, Stang L, van Ryn J, Mitchell LG.

Thromb Res. 2015 Jan 17. pii: S0049-3848(15)00035-3. doi: 10.1016/j.thromres.2015.01.017. [Epub ahead of print]

PMID:
25715905
[PubMed - as supplied by publisher]
Free Article
2.

More indications approved and safety news for dabigatran etexilate.

Cinteza M.

Maedica (Buchar). 2014 Dec;9(4):405-7. No abstract available.

PMID:
25705315
[PubMed]
Free PMC Article
3.

Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device.

Terrovitis JV, Ntalianis A, Kapelios CJ, Vakrou S, Diakos N, Katsaros L, Tsamatsoulis M, Kaldara E, Charitos C, Nanas JN.

Hellenic J Cardiol. 2015 Jan-Feb;56(1):20-5.

PMID:
25701968
[PubMed - in process]
Free Article
4.

What is the role of hemodialysis for dabigatran-associated major bleeding?

Kim B, Garcia DA.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):514-7. doi: 10.1182/asheducation-2014.1.514. Epub 2014 Nov 18.

PMID:
25696903
[PubMed - in process]
5.

Comparison of Renoprotective Effect of Dabigatran With Low-Molecular-Weight Heparin.

Yazici S, Karahan O, Oral MK, Bayramoğlu Z, Unal M, Caynak B, Sagbas E.

Clin Appl Thromb Hemost. 2015 Feb 13. pii: 1076029615571629. [Epub ahead of print]

PMID:
25681331
[PubMed - as supplied by publisher]
6.

[Clinical implications of edoxaban in the current scenario of oral anticoagulants].

De Caterina R.

G Ital Cardiol (Rome). 2014 Dec;15(12):27-9. doi: 10.1714/1744.18990. Italian.

PMID:
25621575
[PubMed - in process]
7.

Acute pulmonary embolism: risk assessment, risk stratification and treatment options.

Piovella F, Iosub DI.

Clin Respir J. 2015 Jan 26. doi: 10.1111/crj.12264. [Epub ahead of print]

PMID:
25619266
[PubMed - as supplied by publisher]
8.

Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.

Stöllberger C, Finsterer J.

Herz. 2015 Jan 25. [Epub ahead of print]

PMID:
25616425
[PubMed - as supplied by publisher]
9.

Identification and Management of Noncompliance in Atrial Fibrillation Patients Receiving Dabigatran: The Role of a Drug Monitor.

Hu YF, Liao JN, Chern CM, Weng CH, Lin YJ, Chang SL, Wu CH, Sung SH, Wang KL, Lu TM, Chao TF, Lo LW, Chung FP, Hsu LC, Chen SA.

Pacing Clin Electrophysiol. 2015 Jan 20. doi: 10.1111/pace.12575. [Epub ahead of print]

PMID:
25601592
[PubMed - as supplied by publisher]
10.

Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.

Schmohl M, Gansser D, Moschetti V, Stangier J.

Thromb Res. 2015 Mar;135(3):532-6. doi: 10.1016/j.thromres.2014.12.021. Epub 2015 Jan 2.

PMID:
25600440
[PubMed - in process]
11.

Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study.

Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA.

J Thromb Haemost. 2015 Jan 16. doi: 10.1111/jth.12845. [Epub ahead of print]

PMID:
25594442
[PubMed - as supplied by publisher]
12.

Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.

Honickel M, Treutler S, van Ryn J, Tillmann S, Rossaint R, Grottke O.

Thromb Haemost. 2015 Jan 8;113(4). [Epub ahead of print]

PMID:
25567155
[PubMed - as supplied by publisher]
13.

Generation of an anti-dabigatran monoclonal antibody and its employment in a highly sensitive and specific enzyme-linked immunosorbent assay for serum dabigatran.

Oiso S, Morinaga O, Goroku T, Uto T, Shoyama Y, Kariyazono H.

Ther Drug Monit. 2015 Jan 6. [Epub ahead of print]

PMID:
25565675
[PubMed - as supplied by publisher]
14.

Left atrial appendage thrombus with resulting stroke post-RF ablation for atrial fibrillation in a patient on dabigatran.

Lobo R, McCann C, Hussaini A, Meany TB, Kiernan TJ.

Ir Med J. 2014 Nov-Dec;107(10):329-30.

PMID:
25551903
[PubMed - indexed for MEDLINE]
15.

[Fatal bleeding diarrhoea during dabigatran etexilate therapy.]

Nyby S, Hennes O.

Ugeskr Laeger. 2014 Dec 15;176(51). pii: V09140482. Danish.

PMID:
25534224
[PubMed - as supplied by publisher]
16.

Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting.

Armbruster AL, Buehler KS, Min SH, Riley M, Daly MW.

Am Health Drug Benefits. 2014 Oct;7(7):376-84.

PMID:
25525494
[PubMed]
Free PMC Article
17.

Laboratory Assessment of the Anticoagulant Activity of Dabigatran.

Kyriakou E, Ikonomidis I, Stylos D, Bonovas S, Papadakis I, Nikolopoulos GK, Kokoris S, Kalantzis D, Economopoulou C, Kopterides P, Lekakis J, Tsantes AE.

Clin Appl Thromb Hemost. 2014 Dec 18. pii: 1076029614564209. [Epub ahead of print]

PMID:
25525048
[PubMed - as supplied by publisher]
18.

Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.

Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Rönquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogné JM, Mullier F.

Thromb Haemost. 2014 Dec 18;113(3). [Epub ahead of print]

PMID:
25519251
[PubMed - as supplied by publisher]
19.

[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].

Beliavskaia OO, Vavilova TV.

Angiol Sosud Khir. 2014;20(4):37-41. Russian.

PMID:
25490355
[PubMed - indexed for MEDLINE]
20.

Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of dabigatran etexilate, intermediate metabolite and dabigatran in 50μL rat plasma and its application to pharmacokinetic study.

Li J, Fang J, Zhong F, Li W, Tang Y, Xu Y, Mao S, Fan G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Oct 8;973C:110-119. doi: 10.1016/j.jchromb.2014.09.025. [Epub ahead of print]

PMID:
25464103
[PubMed - as supplied by publisher]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk